PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

Ke Zhang; Xiangyi Kong; Yuan Li; Zhongzhao Wang; Lin Zhang; Lin Zhang; Lin Zhang; Lixue Xuan

doi:10.3389/fphar.2022.854967

Frontiers in Pharmacology (Mar 2022)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

Ke Zhang,
Xiangyi Kong,
Yuan Li,
Zhongzhao Wang,
Lin Zhang,
Lin Zhang,
Lin Zhang,
Lixue Xuan

Affiliations

Ke Zhang: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Xiangyi Kong: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Yuan Li: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Zhongzhao Wang: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Lin Zhang: School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Lin Zhang: Melbourne School of Population and Global Health, the University of Melbourne, Melbourne, VIC, Australia
Lin Zhang: Centre of Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia
Lixue Xuan: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

DOI: https://doi.org/10.3389/fphar.2022.854967
Journal volume & issue: Vol. 13

Abstract

Read online

Autoimmune diseases and malignant tumors are the two hotspots and difficulties that are currently being studied and concerned by the medical field. The use of PD-1/PD-L1 inhibitors improves the prognosis of advanced tumors, but excessive immune responses can also induce immune-related adverse events (irAEs). Due to this concern, many clinical trials exclude cancer patients with preexisting autoimmune disease (AID). This review outlines the possible mechanisms of irAE, discusses the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients with preexisting AID, and emphasizes the importance of early recognition, continuous monitoring, and multidisciplinary cooperation in the prevention and management of cancer patients with preexisting AID.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords